Table 1.

Baseline characteristics

CharacteristicMGZL (N = 10)
Age, y 35 (25-72) 
>65 1 (10) 
Male 6 (60) 
ECOG performance status  
0-1 9 (90) 
≥2 1 (10) 
Refractory disease  7 (70) 
Bulky disease >10 cm 3 (30) 
Prior systemic cancer therapies, median (range) 2 (1-3)  
Prior therapies 3 (30) 
R-CHOP  
DA-EPOCHR 4 (40) 
Prior auto-HCT 
Time from completion of most recent prior systemic therapy to study treatment, mo  
<3 8 (80) 
3-6 1 (10) 
>6 1 (10) 
CharacteristicMGZL (N = 10)
Age, y 35 (25-72) 
>65 1 (10) 
Male 6 (60) 
ECOG performance status  
0-1 9 (90) 
≥2 1 (10) 
Refractory disease  7 (70) 
Bulky disease >10 cm 3 (30) 
Prior systemic cancer therapies, median (range) 2 (1-3)  
Prior therapies 3 (30) 
R-CHOP  
DA-EPOCHR 4 (40) 
Prior auto-HCT 
Time from completion of most recent prior systemic therapy to study treatment, mo  
<3 8 (80) 
3-6 1 (10) 
>6 1 (10) 

Values are median (range) or n (%).

ECOG, Eastern Cooperative Oncology Group; DA-EPOCHR, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; HCT, hematopoietic stem cell transplantation; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Patient was 72 years old.

No complete remission following frontline therapy, and no complete remission/partial remission to any salvage therapy.

One patient received 2 prior regimens, but 1 regimen was unknown. This patient met the study inclusion criteria, as it was known that they had received 2 prior regimens.

or Create an Account

Close Modal
Close Modal